アブストラクト
| Title | 41. 薬剤アレルギー 4. 重症薬疹の診断・治療 |
|---|---|
| Subtitle | 専門医のためのアレルギー学講座 |
| Authors | 末木博彦 |
| Authors (kana) | |
| Organization | 昭和大学医学部皮膚科学講座 |
| Journal | アレルギー |
| Volume | 70 |
| Number | 2 |
| Page | 86-94 |
| Year/Month | 2021 / |
| Article | 報告 |
| Publisher | 日本アレルギー学会 |
| Abstract | 「はじめに」 薬疹とは経皮投与を除く経路により体内に摂取された薬物自体またはその代謝産物の直接的な作用ないし間接的な作用によって誘導される皮膚粘膜病変と定義される. アレルギー機序によるものを「薬疹」, 薬物の作用機序や毒性に基づくものを「皮膚障害」と区別して呼称される事がある. 重症薬疹とは本来, 患者の生命を脅かしたり, 失明や慢性呼吸障害などの後遺症により患者のQOLを障害する薬疹を指す. 本稿では代表的な重症薬疹について診断と治療を中心に最新の知見を加えて解説したい. 「重症薬疹に共通する抗原認識機構」 従来からアレルギー機序による薬疹はハプテン仮説すなわち抗原として認識され難い分子量の小さい薬物がペプチドと結合し, T細胞レセプター, 抗原提示細胞のHLAと共有結合し感作の過程を経て, 薬剤特異的細胞傷害性T細胞が形成され, 誘発反応により発症すると考えられてきた. |
| Practice | 臨床医学：内科系 |
| Keywords | drug-induced hypersensitivity syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) 池澤善郎. 薬疹とは-診断基準, 臨床病型, その他の薬疹の分類, 重症薬疹. 池澤善郎, 相原道子編. 薬疹のすべて-エキスパートにまなぶ診療の実際-. 東京 : 南江堂 ; 2008. p.3-9.
- 2) Pichler WJ. Delayed drug hypersensitivity reac-tion. Ann Int Med 2003; 139: 683-93.
- 3) Pichler WJ, Adam J, Watkins S, Wuillemin N, Yun J, Yerly D. Drug hypersensitivity: how drugs stimulate T cells via pharmacological interaction with immune receptors. Int Arch Allergy Immmu-nol 2015; 168: 13-24.
- 4) Pichler WJ, Hausmann O. Classification of drug hypersensitivity into allergic, p-i, and pseudo-allergic forms. Int Arch Allergy Immunol 2016; 171: 166-79.
- 5) 北見 周, 渡辺秀晃, 末木博彦, 飯島正文, 相原道子, 池澤善郎, 他. Stevens-Johnson症候群ならびに中毒性表皮壊死症の全国疫学調査-平成20年度厚生労働科学研究費補助金(難治性疾患克服研究事業) 重症多形滲出性紅斑に関する調査研究-. 日皮会誌 2011 ; 121 : 2467-82.
残りの28件を表示する
- 6) Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T. Defective regulatory T cells in patients with severe drug eruptions: tim-ing of the dysfunction is associated with patho-logical phenotype and outcome. J Immunol 2009; 182: 8071-9.
- 7) Shiohara T, Takahashi R, Mizukawa Y. Monocyte-independent and -dependent regula-tion of Treg cell development in mycoplasma in-fection. J Infect Dis 2020; jiaa590. doi:10.1093/infdis/jiaa590.
- 8) Lomax AJ, McQuillan PIA, Hall A, McArthur GA. Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallenge with anti-PD-1 therapy. Intern Med J 2019; 49: 1051-3.
- 9) Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: Re-port of two cases in children. Am J Dis Child 1922; 24: 526-33.
- 10) Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6.
- 11) Sunaga Y, Kurosawa M, Ochiai H, Watanabe H, Sueki H, Azukizawa H, et al. The nationwide epi-demiological survey of Stevens-Johnson syn-drome and toxic epidermal necrolysis in Japan 2016-2018. J Dermatol Sci 2020; 100: 175-82.
- 12) Kunimi Y, Hirata Y, Aihara M, Yamane Y, Ikezawa Z. Statistical analysis of Stevens-Johnson syndrome caused by Mycoplasma pneumonia in-fection in Japan. Allergol Int 2011; 60: 525-32.
- 13) Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necroly-sis. Nat Med 2008; 14: 1343-50.
- 14) Saito N, Qiao H, Yanagi T, Shinkuma S, Nishimura K, Suto A, et al. An annexin A1-FPR1 interaction contributes to necroptosis of keratino-cytes in severe cutaneous adverse drug reac-tions. Sci Transl Med 2014; 6: 245ra95. doi:10.1126/scitranslmed.3008227.
- 15) Hasegawa A, Shinkuma S, Hayashi R, Hama N, Watanabe H, Kinoshita M, et al. RIP3 as a diag-nostic and severity marker for Stevens-Johnson syndrome and toxic epidermal necrolysis. J Al-lergy Clin Immunol Pract 2020; 8: 1768-71.
- 16) 塩原哲夫, 狩野葉子, 水川良子, 佐山浩二, 橋本公二, 藤山幹子, 他. 重症多形滲出性紅斑 スティーヴンス・ジョンソン症候群・中毒性表皮壊死症診療ガイドライン. 日皮会誌 2016 ; 126 : 1637-85.
- 17) Hosaka H, Ohtoshi S, Nakada T, Iijima M. Erythema multiforme, Stevens-Johnson syn-drome and toxic epidermal necrolysis. J Dermatol 2010; 37: 407-12.
- 18) Lyell A. Toxic epidermal necrolysis: an eruptive fever resembling scalding of the skin. Br J Derma-tol 1956; 68: 355-61.
- 19) Oono T, Kanzaki H, Yoshioka T, Arata J. Staphy-lococcal scalded skin syndrome in an adult. Iden-tification of exfoliative toxin A and B genes by po-lymerase chain reaction. Dermatology 1997; 195: 268-70.
- 20) Lucas S. Bacterial diseases. In: Elder DE, et al, editor. Lever's Histopathology of the skin. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p.551-90.
- 21) Shear NH, Spielberg SP. Anticonvulsant hyper-sensitivity syndrome. In vitro assessment of risk. J Clin Invest 1998; 82: 1826-32.
- 22) Tohyama M, Yahata Y, Yasukawa M, Inagi R, Urano Y, Yamanishi K, et al. Severe hypersensi-tivity syndrome due to sulfasalazine associated with reactivation of human herpes virus 6. Arch Dermatol 1998; 134: 1113-7.
- 23) Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T. Human herpes virus 6 infection as a risk factor for the development of severe drug-induced hy-persensitivity syndrome. Arch Dermatol 1998; 134: 1108-12.
- 24) Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syn-drome(Drug Rash with Eosinophilia and Sys-temic symptoms: DRESS). Semin Cutan Med Surg 1996; 15: 250-7.
- 25) Kano Y, Seishima M, Shiohara T. Hypogam-maglobulinemia as an early sign of drug-induced hypersensitivity syndrome. J Am Acad Dermatol 2006; 55: 727-8.
- 26) Ogawa K, Morito H, Hasegawa A, Miyagawa F, Kobayashi N, Watanabe H, et al. Elevated serum thymus and activation-regulated chemokine(TARC/CCL17) relates to reactivation of human herpesvirus 6 in drug reaction with eosinophilia and systemic symptoms(DRESS)/drug-induced hypersensitivity syndrome(DIHS). Br J Dermatol 2014; 171: 425-7.
- 27) Ushigome Y, Kano Y, Ishida T, Hirahara K, Shio-hara T. Short- and long-term outcomes of 34 pa-tients with drug-induced hypersensitivity syn-drome in a single institution. J Am Acad Dermatol 2013; 68: 721-8.
- 28) Sueki H, Mizukawa Y, Aoyama Y. Immune recon-stitution/inflammatory syndrome in non-HIV im-munosuppressed patients. J Dermatol 2018; 45: 3-9.
- 29) 厚生労働省科学研究費補助金 難治性疾患克服研究事業(主任研究者 橋本公二). 難治性疾患(重症多形滲出性紅斑[急性期]を含む)の画期的治療に関する研究. 平成17年度総括・分担研究報告書. 2006. p.1-15.
- 30) Uno H, Kabashima K, Tohyama M, Watanabe T, Hashimoto K, Iijima M, et al. TNF-α as useful pre-dictor of humanherpesvirus-6 reactivation and in-dicator of the disease process in drug reaction with eosinophilia and systemic symptom(DRESS)/drug-induced hypersensitivity syn-drome(DIHS). J Dermatol Sci 2014; 74: 177-9.
- 31) Mizukawa Y, Hirahara K, Kano Y, Shiohara T. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symp-toms severity score: A useful tool for assessing disease severity and predicting fatal cytomega-lovirus disease. J Am Acad Dermatol 2019; 80: 670-8.
- 32) Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transforma-tion test in the diagnosis of drug sensitivity: de-pendence on its timing and the type of drug erup-tion. Allergy 2007; 62: 1439-44.
- 33) 厚生労働省科学研究費補助金 難治性疾患克服研究事業(主任研究者 塩原哲夫). 難治性疾患(重症多形滲出性紅斑[急性期]を含む)の画期的治療に関する研究. 平成24年度総括・分担研究報告書. 2013. p.15-7.
